Frailty is not ECOG: why performance status alone is no longer enough in anticancer therapy

Expert Review of Anticancer Therapy · Published 2026-05-09 · DOI 10.1080/14737140.2026.2673105

Authors being retrieved — see the publisher record. https://doi.org/10.1080/14737140.2026.2673105

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2026

Related articles

The potential impact of glucagon-like peptide 1 receptor agonists for the treatment of endometrial carcinoma · Expert Review of Anticancer Therapy · 2026 · Same journal
Emerging immune checkpoint inhibitor strategies in cervical cancer: a scoping review of ongoing clinical trials · Expert Review of Anticancer Therapy · 2026 · Same journal
Portal vein resection in pancreatic cancer: from technical feasibility to biological patient selection · Expert Review of Anticancer Therapy · 2026 · Same journal
The evolving survival landscape in advanced non-small cell lung cancer: an interrupted time series analysis · Expert Review of Anticancer Therapy · 2026 · Same journal
Angiosarcoma: adaptive designs leveraging vascular biology and antiangiogenic repurposing · Expert Review of Anticancer Therapy · 2026 · Same journal
Quantitative and qualitative fecal immunochemical tests for colorectal cancer screening in Kazakhstan: a comparative study · Expert Review of Anticancer Therapy · 2026 · Same journal
Can we consider stopping hepatocellular carcinoma surveillance in low-risk patients with hepatitis B? · Expert Review of Anticancer Therapy · 2026 · Same journal
Association of neoadjuvant chemotherapy with outcomes in patients with elevated preoperative Ca 19–9 undergoing pancreatic ductal adenocarcinoma resection · Expert Review of Anticancer Therapy · 2026 · Same journal
Cancer genome profiling in sarcomas: current status and future perspectives in Japan · Expert Review of Anticancer Therapy · 2026 · Same journal
Emerging trends in early-onset gastrointestinal cancers - a comparative review with late-onset cancers · Expert Review of Anticancer Therapy · 2026 · Same journal